Figure 3

Epratuzumab induces β1 integrin on CD27^negative B-cells. In order to analyse changes in the surface expression of β1 integrin on B-cell sub-populations (CD27^negative B-cells and CD27^positive B-cells), we incubated PBMCs for 90 minutes at 37°C, 5% CO₂ without epratuzumab (first line), or with human IgG₁ (second line) or with epratuzumab (third line) (n = 3). The histograms are representative of three independent experiments and the results are summarized in Figure 3 (mean ± SEM).